Davies, Elin Haf
Matthews, Clare
Merlet, Adeline
Zimmermann, Martine
Article History
Accepted: 12 December 2021
First Online: 7 January 2022
Change Date: 27 January 2022
Change Type: Update
Change Details: The second Key point sentence has been corrected.
Declarations
:
: No funding was received for the work presented in this manuscript.
: Elin Haf Davies is the CEO of Aparito and is also a shareholder. Clare Matthews is also an employee of Aparito, who are the software provider that delivers SARA<sup>home</sup> for DZNE. Martine Zimmermann and Adeline Merlet are employees of Alexion and AstraZeneca Rare Disease, and own AstraZeneca stock options. Martine Zimmermann is also a Director on the Boards of Caelum Biosciences and Inventive Pharma.
: Not applicable.
: Not applicable.
: All authors provided consent for publication.
: All data reported in this manuscript are publicly available.
: Not applicable.
: All authors contributed to the writing, review, and approval of this manuscript.